Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Accounts Payables (2016 - 2025)

iBio (IBIO) has disclosed Accounts Payables for 15 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 332.25% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 332.25% increase, with the full-year FY2025 number at $2.2 million, up 511.17% from a year prior.
  • Accounts Payables was $2.7 million for Q4 2025 at iBio, down from $2.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.3 million in Q1 2022 to a low of $358000.0 in Q2 2024.
  • A 5-year average of $2.4 million and a median of $2.2 million in 2025 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: tumbled 80.64% in 2024, then skyrocketed 511.17% in 2025.
  • iBio's Accounts Payables stood at $2.7 million in 2021, then surged by 46.11% to $4.0 million in 2022, then tumbled by 53.55% to $1.9 million in 2023, then tumbled by 66.97% to $614000.0 in 2024, then surged by 332.25% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Accounts Payables are $2.7 million (Q4 2025), $2.8 million (Q3 2025), and $2.2 million (Q2 2025).